{
    "id": 16263,
    "fullName": "SMAD4 dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "SMAD4 dec exp indicates decreased expression of the Smad4 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 3257,
                    "pubMedId": null,
                    "title": "The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML",
                    "url": "http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/3632?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=PLX3397&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4089,
        "geneSymbol": "SMAD4",
        "terms": [
            "SMAD4",
            "DPC4",
            "JIP",
            "MADH4",
            "MYHRS"
        ]
    },
    "variant": "dec exp",
    "createDate": "01/07/2016",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12446,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SP600125 demonstrated modest inhibition of Jnk activity and transient growth inhibition in Smad4 knocked-down head and neck squamous cell carcinoma cells in culture (PMID: 28522603).",
            "molecularProfile": {
                "id": 16537,
                "profileName": "SMAD4 dec exp"
            },
            "therapy": {
                "id": 3366,
                "therapyName": "SP600125",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10371,
                    "pubMedId": 28522603,
                    "title": "SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522603"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12461,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, addition of SP600125 to Erbitux (cetuximab) restored sensitivity to Erbitux (cetuximab) in Smad4 knocked-down head and neck squamous cell carcinoma cells in culture (PMID: 28522603).",
            "molecularProfile": {
                "id": 16537,
                "profileName": "SMAD4 dec exp"
            },
            "therapy": {
                "id": 6488,
                "therapyName": "Cetuximab + SP600125",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10371,
                    "pubMedId": 28522603,
                    "title": "SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522603"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4949,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In clinical and meta-analyses, loss of Smad4 expression and SMAD4 inactivating mutations were associated with decreased survival in patients with pancreatic cancer (PMID: 26947875, PMID: 25760429, PMID: 22504380, PMID: 19584151).",
            "molecularProfile": {
                "id": 16537,
                "profileName": "SMAD4 dec exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4806,
                    "pubMedId": 26947875,
                    "title": "Prognostic Value of SMAD4 in Pancreatic Cancer: A Meta-Analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26947875"
                },
                {
                    "id": 5369,
                    "pubMedId": 25760429,
                    "title": "SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25760429"
                },
                {
                    "id": 5370,
                    "pubMedId": 22504380,
                    "title": "SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22504380"
                },
                {
                    "id": 5371,
                    "pubMedId": 19584151,
                    "title": "SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19584151"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3859,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In clinical and meta-analyses, decreased expression of Smad4 was correlated with poor prognosis in colorectal cancer (PMID: 25749173, PMID: 19478385, PMID: 25681512, PMID: 26861460).",
            "molecularProfile": {
                "id": 16537,
                "profileName": "SMAD4 dec exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4241,
                    "pubMedId": 25749173,
                    "title": "A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749173"
                },
                {
                    "id": 5366,
                    "pubMedId": 26861460,
                    "title": "Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26861460"
                },
                {
                    "id": 5367,
                    "pubMedId": 25681512,
                    "title": "Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25681512"
                },
                {
                    "id": 5368,
                    "pubMedId": 19478385,
                    "title": "Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19478385"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12438,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, decreased Smad4 expression level correlated with Erbitux (cetuximab) resistance in head and neck squamous cell carcinoma (HNSCC) patients, which is consistent with cell culture studies demonstrating Erbitux (cetuximab) resistance induced by knocking-down of Smad4 expression in HNSCC cell lines (PMID: 28522603).",
            "molecularProfile": {
                "id": 16537,
                "profileName": "SMAD4 dec exp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10371,
                    "pubMedId": 28522603,
                    "title": "SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522603"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12452,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, U0126 demonstrated modest inhibition of Mapk activity and transient growth inhibition in Smad4 knocked-down head and neck squamous cell carcinoma cells in culture (PMID: 28522603).",
            "molecularProfile": {
                "id": 16537,
                "profileName": "SMAD4 dec exp"
            },
            "therapy": {
                "id": 2427,
                "therapyName": "U0126",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10371,
                    "pubMedId": 28522603,
                    "title": "SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522603"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12458,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, addition of U0126 to Erbitux (cetuximab) restored sensitivity to Erbitux (cetuximab) in Smad4 knocked-down head and neck squamous cell carcinoma cells in culture (PMID: 28522603).",
            "molecularProfile": {
                "id": 16537,
                "profileName": "SMAD4 dec exp"
            },
            "therapy": {
                "id": 6489,
                "therapyName": "Cetuximab + U0126",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10371,
                    "pubMedId": 28522603,
                    "title": "SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522603"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 16537,
            "profileName": "SMAD4 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}